0001104659-20-068535.txt : 20200601 0001104659-20-068535.hdr.sgml : 20200601 20200601190423 ACCESSION NUMBER: 0001104659-20-068535 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200528 FILED AS OF DATE: 20200601 DATE AS OF CHANGE: 20200601 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gottesdiener Keith Michael CENTRAL INDEX KEY: 0001615856 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35668 FILM NUMBER: 20935226 MAIL ADDRESS: STREET 1: 900 FIFTH AVENUE STREET 2: #8C CITY: NEW YORK STATE: NY ZIP: 10021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INTERCEPT PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001270073 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223868459 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 HUDSON YARDS, 37TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 646-747-1000 MAIL ADDRESS: STREET 1: 10 HUDSON YARDS, 37TH FLOOR CITY: New York STATE: NY ZIP: 10001 FORMER COMPANY: FORMER CONFORMED NAME: INTERCEPT PHARMACEUTICALS INC DATE OF NAME CHANGE: 20031113 4 1 tm2021501d6_4.xml OWNERSHIP DOCUMENT X0306 4 2020-05-28 0 0001270073 INTERCEPT PHARMACEUTICALS, INC. ICPT 0001615856 Gottesdiener Keith Michael C/O INTERCEPT PHARMACEUTICALS, INC. 10 HUDSON YARDS, FLOOR 37 NEW YORK NY 10001 1 0 0 0 Common Stock 2020-05-28 4 A 0 1595 0 A 9953 D Option to Purchase Common Stock 72.74 2020-05-28 4 A 0 2966 0 A 2030-05-28 Common Stock 2966 2966 D Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. /s/ Mark Pruzanski, as attorney-in-fact 2020-06-01